Radius Health, Inc.

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Its commercial product includes TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It also develops abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for the treatment of hyperphagia related to Prader-Willi syndrome. Radius Health, Inc. has a partnership with EffRx Pharmaceuticals. Radius Health, Inc. was formerly known as MPM Acquisition Corp. and changed its name to Radius Health, Inc. in May 2011. The company was incorporated in 2003 and is based in Boston, Massachusetts.